ABT - Abbott Laboratories
A diversified healthcare company spanning diagnostics, medical devices, nutrition, and established pharmaceuticals, with a strong presence in rapid testing and cardiac devices.
Finlify Score
22.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$101.95
-1.36%
52W Range
$81.97 - $137.49
Market Cap
$191.0B
-1.4%Compared to previous day
2026 Q1 Revenue
$11.2B
-2.6%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
33 analysts in latest ratings feed
RSI
12.5
<40 oversold
2Y Range Position
34%
-27.8% from high / +24.4% from low
Beta
0.55
Relative to market benchmark
MACD
-1.67
MACD line -0.55 / signal line 1.11
Fundamental Trend
Growth 9.7Financial Health
Quality 44.8Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID22.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $11.2B-2.6% | $11.5B+0.8% | $11.4B+2.0% | $11.1B+7.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.3B-40.2% | $2.3B+9.4% | $2.1B+0.2% | $2.1B+21.2% |
| Net Income | $1.1B-39.4% | $1.8B+8.0% | $1.6B-7.6% | $1.8B+34.3% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
The Finlify signal for Abbott Laboratories (ABT) on 2026-07-30 is AVOID, with a Finlify Score of 29.8 out of 100. This low score appears primarily driven by a very weak Fundamental Trend score of 9.7/100 and low Relative Strength at 16.3/100.
Technical
Despite recent strong short-term performance with a 20-day return of 14.6% and a 60-day return of 20.6%, the asset's Relative Strength score is notably low at 16.3/100, which may indicate underperformance over a broader period. The RSI(14) at 66.6 suggests the asset is approaching overbought conditions, while it remains 19.1% below its 52-week high. The Accumulation / Volume score of 70.2/100 suggests some positive buying interest.
Fundamentals
The Fundamental Trend score of 9.7/100 is a significant detractor, suggesting a deteriorating fundamental outlook for ABT. The Financial Quality score is moderate at 44.8/100. Valuation metrics appear somewhat elevated, with a P/E ratio of 28.0x and a P/S ratio of 4.1x, especially when considered against the weak fundamental trend. The asset offers a dividend yield of 2.39% and exhibits lower volatility with a Beta of 0.6.
Macro Context
In an environment with a positive but narrow yield spread of 0.5% and inflation measures like Core CPI at 2.8% and Core PCE at 3.3%, the relatively high 10Y Treasury Yield of 4.7% could potentially make growth assets like ABT less attractive compared to fixed-income alternatives, especially given its elevated valuation multiples.
Key Risks
- The extremely low Fundamental Trend score of 9.7/100 suggests significant underlying issues with the company's financial health or growth prospects.
- Despite recent positive returns, the very low Relative Strength score of 16.3/100 indicates that ABT may be underperforming its peers or the broader market over a longer timeframe.
- The P/E ratio of 28.0x appears somewhat high, which may suggest the asset is fully valued, particularly in light of its weak fundamental trend and the current macro environment.